Alnylam Pharmaceuticals, Inc. (ALNY) Stock Price & Analysis
Alnylam Pharmaceuticals, Inc. (ALNY) rose 1.89% to USD 297.69 as of June 9, 2026 at 23:48 UTC, according to Nexqual real-time market data.
ALNY last closed at USD 292.16; the session ranged USD 294.03–302.85 on volume of 1,226,030 shares. Market capitalization is $39.75B, with a 52-week range of USD 283.1–495.55 (NMS). Source: Nexqual, June 9, 2026 at 23:48 UTC.
Key Statistics (as of June 9, 2026 at 23:48 UTC)
| Price | USD 297.69 |
|---|---|
| Change | ▲ 1.89% (up) |
| Previous Close | USD 292.16 |
| Open | USD 297.31 |
| Day Range | USD 294.03 – 302.85 |
| 52-Week Range | USD 283.1 – 495.55 |
| Volume | 1,226,030 shares |
| Market Cap | $39.75B |
| Exchange | NMS |
Technical Analysis (ALNY)
Nexqual's technical model rates ALNY "NEUTRAL" based on 2 bullish and 3 bearish signals across 124 daily candles, as of June 9, 2026 at 23:48 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 48.72 (neutral) |
| vs SMA50 | Below (USD 306.1) |
| MACD | -1.78 (negative) |
Analyst Ratings (ALNY)
Wall Street analysts rate ALNY "Buy" based on 26 analysts, with a mean price target of USD 441.31 (range USD 310–566), per Nexqual as of June 9, 2026 at 23:48 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 26 |
| Mean Target | USD 441.31 |
| High Target | USD 566 |
| Low Target | USD 310 |
| Buy / Hold / Sell | 22 / 8 / 0 |
Earnings (ALNY)
| Next Earnings Date | 2026-07-30 |
|---|---|
| EPS Estimate | USD 2.17 |
| Revenue Estimate | $1.32B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.99 vs est 1.47 ▲ beat |
| 2025-12-31 | USD 1.25 vs est 1.5 ▼ miss |
| 2025-09-30 | USD 2.9 vs est 1.75 ▲ beat |
| 2025-06-30 | USD 0.32 vs est 0.15 ▲ beat |
Source: Nexqual, June 9, 2026 at 23:48 UTC.
Financials & Fundamentals (ALNY)
| Total Revenue | $4.29B |
|---|---|
| Revenue Growth (YoY) | +96.40% |
| Gross Margin | +80.83% |
| Operating Margin | +23.02% |
| Profit Margin | +12.55% |
| ROE | +90.36% |
| Debt / Equity | 276.2 |
| Current Ratio | 3.13 |
| Total Cash | $3.01B |
| Total Debt | $2.97B |
| Free Cash Flow | $204.71M |
Source: Nexqual, June 9, 2026 at 23:48 UTC.
Financial Health Score (ALNY)
Nexqual rates Alnylam Pharmaceuticals, Inc.'s overall financial health "Solid" across five dimensions, as of June 9, 2026 at 23:48 UTC.
| Growth | Strong — Revenue +65% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 81%, operating 23% |
| Balance Sheet | Weak — $3.01B cash vs $2.97B debt, net cash position |
| Cash Flow | Solid — FCF $205M, 6% margin |
| Efficiency | Strong — ROE 90%, ROA 10.1% |
Ownership (ALNY)
| Insider Ownership | +0.18% |
|---|---|
| Institutional Ownership | +102.08% |
| Shares Outstanding | 133.51M |
| Float | 132.94M |
| Short % of Float | +5.29% |
Source: Nexqual, June 9, 2026 at 23:48 UTC.
Leadership (ALNY)
Alnylam Pharmaceuticals, Inc. is led by Yvonne L. Greenstreet (age 62), CEO & Director, per Nexqual as of June 9, 2026 at 23:48 UTC.
| CEO & Director | Yvonne L. Greenstreet (age 62) |
|---|---|
| CFO & Executive VP | Jeffrey V. Poulton (age 57) |
| Executive VP, Chief Scientific Officer and Head of Early Research & Early Development | Kevin Joseph Fitzgerald (age 57) |
Major Backers & Investors (ALNY)
Notable institutional backers of Alnylam Pharmaceuticals, Inc. include Capital Group, FMR, LLC, JPMorgan, according to Nexqual as of June 9, 2026 at 23:48 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Capital Group | 15.18% |
| FMR, LLC | 10.92% |
| JPMorgan | 6.27% |
| GROWTH FUND OF AMERICA | 6.01% |
| T. Rowe Price | 5.18% |
| AMCAP FUND | 2.8% |
| Invesco | 2.13% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 15.79% |
| BlackRock | 7.82% |
| State Street | 2.49% |
Source: Nexqual, June 9, 2026 at 23:48 UTC.
From Alnylam Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-12)
Key Strengths & Strategy (as disclosed to the SEC)
- In March 2025, the United States Food and Drug Administration, or the FDA, approved our supplemental New Drug Application, or sNDA, for AMVUTTRA for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits.
- In parallel, we advanced a proprietary technology that conjugates a sugar molecule, referred to as GalNAc, to the siRNA molecule.
- We believe this success will enable us to sustainably and organically create and commercialize transformative medicines that benefit patients around the world across a broad range of disease areas and indications.
Partnerships
- In addition, we are exploring peptide and antibody-based approaches for targeted siRNA delivery to new tissues, including as part of our collaboration with PeptiDream, Inc., which aims to discover and develop novel conjugates for targeted delivery of RNAi therapeutics to a broader range of tissues.
- We also intend to continue to build on our progress with extrahepatic delivery during 2026, advancing our CNS programs under our collaboration with Regeneron, as well as continuing to advance our other extrahepatic delivery initiatives, in support of our Alnylam 2030 goal to expand to ten tissue types by the end of 2030.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BMRN | BioMarin Pharmaceutical Inc. | USD 57.91 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 74.58 | ▲ 0.13% |
| INCY | Incyte Corporation | USD 103.23 | ▲ 0.83% |
| NBIX | Neurocrine Biosciences, Inc. | USD 165.24 | ▲ 0.83% |
| SRPT | Sarepta Therapeutics, Inc. | USD 15.89 | ▲ 0.89% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:48 UTC. This page is informational and not investment advice.